To address this knowledge gap. we used performance-based measures of several dimensions of impulsiveness
to assess whether people engaging in non-suicidal self-injury (NSSI) demonstrate greater impulsiveness than non-injurers. In Study 1, we compared adolescent self-injurers (n = 64) to age-, sex-, and race/ethnicity-matched, non-injurious controls (n. = 30) on self-reported impulsiveness (Schedule for Affective Disorders and Schizophrenia for School Age Children. Present and LifetimeVersion) and on performance-based measures of two dimensions ofi mpulsiveness: behavioral disinhibition (Conners’ Continuous Performance Test) and risky decision-making (Iowa Gambling Task). In Study 2, we compared adult female self-injurers (n = 20) with age- and race/ethnicity-matched, non-injurious controls (n = 20) on self-reported Staurosporine datasheet impulsiveness (Barratt Impulsiveness Scale-11), and performance-based measures
of behavioral disinhibition, risky decision-making. and two measures PU-H71 clinical trial of delay discounting. In both studies, self-injurers reported greater impulsiveness; however. performance-based measures of impulsiveness failed to detect any between-group differences. We propose several potential explanations for the discrepancies observed between self-report and performance-based measures of impulsiveness and discuss directions for future research on impulsiveness and Birinapant research buy self-injury. (C) 2008 Elsevier Ireland Ltd. All rights reserved.”
“Chronic graft-versus-host disease (cGVHD) remains a major cause of non-relapse morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Currently there are no accepted measures of cGVHD activity to aid in clinical
management and disease staging. We analyzed clinical markers of inflammation in the sera of patients with established cGVHD and correlated those with definitions of disease activity. In all, 189 adults with cGVHD (33% moderate and 66% severe according to National Institutes of Health (NIH) global scoring) were consecutively enrolled onto a cross-sectional prospective cGVHD natural history study. At the time of evaluation, 80% were receiving systemic immunosuppression and failed a median of four prior systemic therapies (PST) for their cGVHD. Lower albumin (P < 0.0001), higher C-reactive protein (P = 0.043), higher platelets (P = 0.030) and higher number of PST (P < 0.0001) were associated with active disease defined as clinician’s intention to intensify or alter systemic therapy due to the lack of response. Higher platelet count (P = 0.021) and higher number of PST (P < 0.0001) were associated with more severe diseased defined by NIH global score. This study identified common laboratory indicators of inflammation that can serve as markers of cGVHD activity and severity. Leukemia (2012) 26, 633-643; doi:10.1038/leu.2011.